GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2009

New HD Research Center Tasked with Preventing, Treating, or Curing Disease by 2020

  • The J. David Gladstone Institutes, Taube Philanthropies, and the Koret Foundation joined forces to initiate a research program aimed at preventing, treating, or curing Huntington's disease (HD) by 2020.

    The new Taube-Koret Center for Huntington's Disease Research has been established at the Gladstone Center for Translational Research at Mission Bay, CA, with $3.6 million in funding from the two organizations. The program is called HD Cure 2020.

    The center will build on research from investigators Steven Finkbeiner, M.D., Ph.D., and Paul Muchowski, Ph.D., of the Gladstone Institute of Neurological Disease (GIND) related to assay development and molecular targets that may modulate HD progression.

    Dr. Finkbeiner’s technologies reportedly aid in the understanding of HD etiology and pathology. Dr. Muchowski’s studies  have identified  intracellular pathways that modify progression of the disease. Together they have also developed methods to find and screen small molecules that may work to modulate the disease.

    “While so much is known about Huntington's disease, it remains an unsolved mystery,” notes Dr. Finkbeiner. “Over the last few years, we have been able to find new points of entry into how the disease progresses and where we might possibly intervene.”



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?